Gilead Sciences, Inc.
NEWS
The survey showed that not surprisingly, patients by and large have negative views of the pharma industry when it comes to corporate responsibility and pricing -- mostly pricing.
Here’s a look at six San Francisco Bay Area life science companies that have hit a variety of “best of” lists recently, in no particular order.
Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.
The San Francisco Business Times came out with a list of 64 major Bay Area employers and their median pay, which they then compared to their chief executives’ annual compensation.
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
As the International Liver Conference continues to unfold in Vienna, multiple companies are presenting data on potential treatments that can address numerous needs. BioSpace takes a look at some of the data.
The loss of patent protection on two drugs is forcing Gilead Sciences to terminate about 20 percent of its sales team, according to reports.
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
Gilead Sciences and Belgium-based Galapagos NV reported positive late-stage results from its FINCH 1 and FINCH 3 rheumatoid arthritis studies.
JOBS
IN THE PRESS